SINT launches FDA-cleared foot device, raises capital via ATM, but going concern doubt returns

Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~1 min read

Key Changes

• high

  Going concern assessment reversed: despite FDA clearance, ATM capital access, and cost cuts, management now cites substantial doubt about 12-month viability vs. prior year's 'no uncertainty' stance.

  MD&A: Going Concern verify on EDGAR →
• high

  FDA cleared SiNAPTIC Foot & Ankle system in Oct 2025; Q1 2026 revenue recognized, expected to grow through year. First commercial entry into reconstructive foot/ankle surgery.

  MD&A: Product Launch verify on EDGAR →
• high

  Cash burn accelerated 92% to $2.5M in Q1 2026 vs. $1.3M prior year; net loss rose 23% to $2.8M despite cost actions. Accumulated deficit now $295M.

  MD&A: Cash Usage verify on EDGAR →